This Perspective explores the application of machine learning toward improved diagnosis
and treatment. We outline a vision for how machine learning can transform three broad areas …

The Library of Integrated Network-Based Cellular Signatures (LINCS) is an NIH Common
Fund program that catalogs how human cells globally respond to chemical, genetic, and …

Compared with normal cells, tumor cells have undergone an array of genetic and epigenetic
alterations. Often, these changes underlie cancer development, progression, and drug …

Predicting the best treatment strategy from genomic information is a core goal of precision
medicine. Here we focus on predicting drug response based on a cohort of genomic, …

Breast cancers are comprised of molecularly distinct subtypes that may respond differently to
pathway-targeted therapies now under development. Collections of breast cancer cell lines …

Specific inhibitors of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK)
kinase (MEK) have been developed that efficiently inhibit the oncogenic RAF-MEK-…

Large-scale analysis of cellular response to anticancer drugs typically focuses on variation
in potency (half-maximum inhibitory concentration, (IC 50 )), assuming that it is the most …

KRAS mutation is a hallmark of pancreatic ductal adenocarcinoma (PDA) but remains an
intractable pharmacologic target. Consequently, defining RAS effector pathway(s) required for …

Background First-generation molecular profiles for human breast cancers have enabled the
identification of features that can predict therapeutic response; however, little is known about …

Recent therapeutic successes have renewed interest in drug combinations, but experimental
screening approaches are costly and often identify only small numbers of synergistic …